Jude Total Therapy Study 15, only low-risk B-ALL patients with ETV6-RUNX1-postive or hyperdiploid > 50 ALL and negative MRD ( < 1 × 10–4) on day 19 of remission induction had a low cumulative risk of relapse (1.9% and 3.8%, respectively) as compared to an unacceptably high cumulative risk of relapse (9.5%) in low-risk (i.e., NCI standard-risk B-ALL) patients with other genotypes and negative MRD on day 19 [18]. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.